Abstract
Cardiovascular diseases are the leading cause of death worldwide, and cell-based therapies represent a potential cure for patients with cardiac diseases such as myocardial infarction, heart failure, and congenital heart diseases. Towards this goal, cardiac tissue engineering is now being investigated as an approach to support cell-based therapies and enhance their efficacy. This review focuses on the latest research in cardiac tissue engineering based on the use of embryonic, induced pluripotent, or adult stem cells. We describe different strategies such as direct injection of cells and/or biomaterials as well as direct replacement therapies with tissue mimics. In this regard, the latest research has shown promising results demonstrating the improvement of cardiac function with different strategies. It is clear from recent studies that the most important consideration to be addressed by new therapeutic strategies is long-term functional improvement. For this goal to be realized, novel and efficient methods of cell delivery are required that enable high cell retention, followed by electrical integration and mechanical coupling of the injected cells or the engineered tissue to the host myocardium.
Similar content being viewed by others
References
Boilson, B. A., et al. (2010). Device therapy and cardiac transplantation for end-stage heart failure. Current Problems in Cardiology, 35(1), 8–64.
Kirkpatrick, J. N., Wiegers, S. E., & Lang, R. M. (2010). Left ventricular assist devices and other devices for end-stage heart failure: utility of echocardiography. Current Cardiology Reports, 12(3), 257–264.
Nelson, T. J., Behfar, A., & Terzic, A. (2008). Strategies for therapeutic repair: The “R3” regenerative medicine paradigm. Clinical and Translational Science, 1(2), 168–171.
Murry, C. E., Reinecke, H., & Pabon, L. M. (2006). Regeneration gaps: Observations on stem cells and cardiac repair. Journal of the American College of Cardiology, 47(9), 1777–1785.
Rossini, R., et al. (2010). Prevention of left ventricular remodelling after acute myocardial infarction: An update. Recent Patents on Cardiovascular Drug Discovery, 5(3), 196–207.
Radisic, M., et al. (2008). Cardiac tissue engineering using perfusion bioreactor systems. Nature Protocols, 3(4), 719–738.
Reinecke, H., et al. (1999). Survival, integration, and differentiation of cardiomyocyte grafts: A study in normal and injured rat hearts. Circulation, 100(2), 193–202.
Herrmann, J. L., et al. (2009). Cell-based therapy for ischemic heart disease: A clinical update. The Annals of Thoracic Surgery, 88(5), 1714–1722.
Yoon, S. J., et al. (2009). Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. Journal of Biomedical Materials Research. Part B, Applied Biomaterials, 91(1), 163–171.
Singelyn, J. M., & Christman, K. L. (2010). Injectable materials for the treatment of myocardial infarction and heart failure: The promise of decellularized matrices. Journal of Cardiovascular Translational Research, 3(5), 478–486.
Christoforou, N., et al. (2010). Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts. PloS One, 5(7), e11536.
Adler, E. D., et al. (2010). The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction. The FASEB Journal, 24(4), 1073–1081.
Caspi, O., et al. (2007). Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of the American College of Cardiology, 50(19), 1884–1893.
Fernandes, S., et al. (2010). Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. Journal of Molecular and Cellular Cardiology, 49(6), 941–949.
Laflamme, M. A., et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25(9), 1015–1024.
van Laake, L. W., et al. (2009). Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Research, 3(2–3), 106–112.
Nelson, T. J., et al. (2009). Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation, 120(5), 408–416.
Lu, W. N., et al. (2009). Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Engineering. Part A, 15(6), 1437–1447.
Fujimoto, K. L., et al. (2009). Naive rat amnion-derived cell transplantation improved left ventricular function and reduced myocardial scar of postinfarcted heart. Cell Transplantation, 18(4), 477–486.
Smits, A. M., et al. (2009). Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovascular Research, 83(3), 527–535.
Landa, N., et al. (2008). Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation, 117(11), 1388–1396.
Wall, S. T., et al. (2010). Biomimetic matrices for myocardial stabilization and stem cell transplantation. Journal of Biomedical Materials Research. Part A, 95(4), 1055–1066.
Dengler, J., et al. (2010). Engineered heart tissue enables study of residual undifferentiated embryonic stem cell activity in a cardiac environment. Biotechnol Bioeng, 108, 704–719.
Hansen, A., et al. (2010). Development of a drug screening platform based on engineered heart tissue. Circulation Research, 107(1), 35–44.
Passier, R., van Laake, L. W., & Mummery, C. L. (2008). Stem-cell-based therapy and lessons from the heart. Nature, 453(7193), 322–329.
Segers, V. F. M., & Lee, R. T. (2008). Stem-cell therapy for cardiac disease. Nature, 451(7181), 937–942.
Gnecchi, M., et al. (2005). Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nature Medicine, 11(4), 367–368.
Jawad, H., et al. (2007). Myocardial tissue engineering: A review. Journal of Tissue Engineering and Regenerative Medicine, 1(5), 327–342.
De Falco, M., Cobellis, G., & De Luca, A. (2009). Proliferation of cardiomyocytes: A question unresolved. Frontiers in Bioscience (Elite Ed), 1, 528–536.
Thomson, J. A., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145–1147.
Stevens, K. R., et al. (2009). Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proceedings of the National Academy of Sciences of the United States of America, 106(39), 16568–16573.
Stevens, K. R., et al. (2009). Scaffold-free human cardiac tissue patch created from embryonic stem cells. Tissue Engineering. Part A, 15(6), 1211–1222.
Kreutziger, K. L., & Murry, C. E. (2011). Engineered human cardiac tissue. Pediatr Cardiol, 32, 334–341.
Ke, Q., et al. (2005). Embryonic stem cells cultured in biodegradable scaffold repair infarcted myocardium in mice. Sheng Li Xue Bao, 57(6), 673–681.
Nussbaum, J., et al. (2007). Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. The FASEB Journal, 21(7), 1345–1357.
Chen, Q. Z., et al. (2010). An elastomeric patch derived from poly(glycerol sebacate) for delivery of embryonic stem cells to the heart. Biomaterials, 31(14), 3885–3893.
Engelmayr, G. C., Jr., et al. (2008). Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nature Materials, 7(12), 1003–1010.
Guo, X. M., et al. (2006). Creation of engineered cardiac tissue in vitro from mouse embryonic stem cells. Circulation, 113(18), 2229–2237.
Gwak, S. J., et al. (2008). The effect of cyclic strain on embryonic stem cell-derived cardiomyocytes. Biomaterials, 29(7), 844–856.
Boyd, N. L., et al. (2011). Microvascular mural cell functionality of human embryonic stem cell-derived mesenchymal cells. Tissue Eng Part A, 15, 1897–1907.
Ferreira, L. S., et al. (2007). Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circulation Research, 101(3), 286–294.
Levenberg, S., et al. (2002). Endothelial cells derived from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 99(7), 4391–4396.
Kraehenbuehl, T. P., et al. (2010). Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials, 32(4), 1102–1109.
Caspi, O., et al. (2007). Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circulation Research, 100(2), 263–272.
Lesman, A., et al. (2010). Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Engineering. Part A, 16(1), 115–125.
Zhang, J., et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104(4), e30–e41.
Deb, A., et al. (2003). Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation, 107(9), 1247–1249.
Jackson, K. A., et al. (2001). Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. The Journal of Clinical Investigation, 107(11), 1395–1402.
Orlic, D., et al. (2003). Bone marrow stem cells regenerate infarcted myocardium. Pediatric Transplantation, 7(Suppl 3), 86–88.
Orlic, D., et al. (2001). Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proceedings of the National Academy of Sciences of the United States of America, 98(18), 10344–10349.
Rosenzweig, A. (2006). Cardiac cell therapy—mixed results from mixed cells. The New England Journal of Medicine, 355(12), 1274–1277.
Oh, H., et al. (2003). Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proceedings of the National Academy of Sciences of the United States of America, 100(21), 12313–12318.
Beltrami, A. P., et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114(6), 763–776.
Laugwitz, K. L., et al. (2005). Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature, 433(7026), 647–653.
Domian, I. J., et al. (2009). Generation of functional ventricular heart muscle from mouse ventricular progenitor cells. Science, 326(5951), 426–429.
Johnston, P. V., et al. (2009). Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation, 120(12), 1075–1083. 7 p following 1083.
Messina, E., et al. (2004). Isolation and expansion of adult cardiac stem cells from human and murine heart. Circulation Research, 95(9), 911–921.
Chimenti, I., et al. (2010). Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circulation Research, 106(5), 971–980.
Cheng, K., et al. (2010). Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circulation Research, 106(10), 1570–1581.
Alper, J. (2009). Geron gets green light for human trial of ES cell-derived product. Nat Biotech, 27(3), 213–214.
Chen, S. L., et al. (2004). Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The American Journal of Cardiology, 94(1), 92–95.
Herreros, J., et al. (2003). Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. European Heart Journal, 24(22), 2012–2020.
Menasche, P., et al. (2003). Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. Journal of the American College of Cardiology, 41(7), 1078–1083.
Murry, C. E., Field, L. J., & Menasche, P. (2005). Cell-based cardiac repair: Reflections at the 10-year point. Circulation, 112(20), 3174–3183.
Pagani, F. D., et al. (2003). Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. Journal of the American College of Cardiology, 41(5), 879–888.
Siminiak, T., et al. (2004). Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. American Heart Journal, 148(3), 531–537.
Sung, N. S., et al. (2003). Central challenges facing the national clinical research enterprise. JAMA, 289(10), 1278–1287.
Wollert, K. C., et al. (2004). Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet, 364(9429), 141–148.
Hotta, A., & Ellis, J. (2008). Retroviral vector silencing during iPS cell induction: An epigenetic beacon that signals distinct pluripotent states. Journal of Cellular Biochemistry, 105(4), 940–948.
Maherali, N., et al. (2007). Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell, 1(1), 55–70.
Woltjen, K., et al. (2009). Piggybac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 27, 559–567.
Laflamme, M. A., & Murry, C. E. (2005). Regenerating the heart. Nature Biotechnology, 23(7), 845–856.
Dengler, J., & Radisic, M. (2007). Tissue engineering approaches for the development of a contractile cardiac patch. Future Cardiology, 3(4), 425–434.
Shimizu, T., et al. (2009). Cell sheet-based myocardial tissue engineering: New hope for damaged heart rescue. Current Pharmaceutical Design, 15(24), 2807–2814.
Zimmermann, W. H., et al. (2006). Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nature Medicine, 12(4), 452–458.
Song, H., et al. (2010). Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. Proceedings of the National Academy of Sciences of the United States of America, 107(8), 3329–3334.
Song, H., Zandstra, P. W., and Radisic, M. (2011). Engineered Heart Tissue Model of Diabetic Myocardium. Tissue Eng Part A.
Acknowledgments
Financial support for our work is provided by a Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant (RGPIN 326982–10), Discovery Accelerator Supplement (RGPAS 396125–10), NSERC Strategic Grant (STPGP 381002–09), NSERC-Canadian Institutes of Health Research Collaborative Health Research Grant (CHRPJ 385981–10), and Heart and Stroke Foundation of Ontario Grant-in-Aid (T6946).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Nunes, S.S., Song, H., Chiang, C.K. et al. Stem Cell-Based Cardiac Tissue Engineering. J. of Cardiovasc. Trans. Res. 4, 592–602 (2011). https://doi.org/10.1007/s12265-011-9307-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-011-9307-x